Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-05-11
DOI
10.3389/fonc.2021.651745
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)
- (2021) Thomas W. Flaig et al. CLINICAL CANCER RESEARCH
- Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.
- (2020) Shilpa Gupta et al. JOURNAL OF CLINICAL ONCOLOGY
- Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
- (2020) Thomas W. Flaig et al. Journal of the National Comprehensive Cancer Network
- European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
- (2020) J. Alfred Witjes et al. EUROPEAN UROLOGY
- DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature.
- (2020) Enrique Grande et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses
- (2020) Christian Pfister et al. EUROPEAN UROLOGY
- Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
- (2020) Nick van Dijk et al. NATURE MEDICINE
- Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor
- (2019) M. Ferro et al. WORLD JOURNAL OF UROLOGY
- Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD–SIU joint consultation on bladder cancer
- (2018) Mario I. Fernández et al. WORLD JOURNAL OF UROLOGY
- Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis
- (2016) Ming Yin et al. ONCOLOGIST
- Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
- (2015) Matthew D. Galsky et al. CANCER
- Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: A systematic review
- (2015) Giuseppe Di Lorenzo et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms
- (2011) Alberto Abbruzzese ONCOLOGY REPORTS
- Long-term cardiovascular risk following platinum-based chemotherapy for germ cell tumors
- (2010) Clary Evans et al. Future Oncology
- A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder
- (2008) Atreya Dash et al. CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation